Correction: *Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies*

Michielin O, Lalani A, Robert C, *et al*. Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies. *J Immunother Cancer* 2022;10:e003024. doi: 10.1136/jitc-2021-003024

Figures 1 and 6 have been updated. References 155 and 157 have been updated.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

J Immunother Cancer 2022;**10**:e003024corr1. doi:10.1136/jitc-2021-003024corr1

Check for updates

J Immunother Cancer: first published as 10.1136/jitc-2021-003024corr1 on 21 December 2022. Downloaded from http://jitc.bmj.com/ on April 17, 2024 by guest. Protected by copyright.